SA
Go ProLog In
IOVA
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
20 analysts·High coverage
69
Score
15 Buy (75%)5 Hold (25%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1575%
Hold
525%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$2.00
-42.2%
Consensus
$2.00
-42.2%
Bull
$2.00
-42.2%
12-Month Target Range20 analysts
$2.00$2.00$2.00
Current $3.46Consensus
Current Price
$3.46
Above Consensus
$1.46

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+37.22%
EPS—
FY2028
Rev+45.66%
EPS—
FY2029
Rev+32.38%
EPS+67937.97%

Earnings Surprises

Recent Analyst Actions

Feb 5, 2026Goldman Sachs
Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs
Target:$2.00
-18.0%from $2.44
May 16, 2025UBS
Iovance Biotherapeutics downgraded to Neutral from Buy at UBS
Target:$2.00
+20.5%from $1.66
Feb 28, 2025Piper Sandler
Iovance Biotherapeutics price target lowered to $6 from $7.50 at Piper Sandler
Target:$6.00
+41.5%from $4.24
Jan 31, 2025Piper Sandler
Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler
Target:$7.50
+28.2%from $5.85
Oct 24, 2024UBS
UBS Starts Iovanace Biotherapeutics (IOVA) at Buy
Target:$17.00
+73.1%from $9.82
Aug 9, 2024Stifel Nicolaus
Iovanace Biotherapeutics (IOVA) PT Lowered to $23 at Stifel
Target:$23.00
+479.3%from $3.97
Aug 9, 2024Robert W. Baird
Iovanace Biotherapeutics (IOVA) PT Lowered to $24 at Baird
Target:$24.00
+504.5%from $3.97
Jul 29, 2024Piper Sandler
Piper Sandler Downgrades Iovanace Biotherapeutics (IOVA) to Neutral
Target:$10.00
+8.1%from $9.25
Jun 20, 2024JMP Securities
Iovance Biotherapeutics price target lowered to $23 from $25 at JMP Securities
Target:$23.00
+475.0%from $4.00
May 31, 2024Stifel Nicolaus
Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
Target:$28.00
+530.6%from $4.44
Mar 14, 2024Piper Sandler
Iovanace Biotherapeutics (IOVA) PT Raised to $19 at Piper Sandler
Target:$19.00
+33.7%from $14.21
Dec 8, 2022Goldman Sachs
Iovance Biotherapeutics downgraded to Neutral from Buy at Goldman Sachs
Target:$6.00
-16.3%from $7.17
Nov 20, 2022Piper Sandler
Iovance Biotherapeutics price target lowered to $11 from $13 at Piper Sandler
Target:$11.00
+66.2%from $6.62
Aug 23, 2022Robert W. Baird
Iovance Biotherapeutics (IOVA) Stock: $25 Target And Outperform Rating
Target:$25.00
+334.8%from $5.75
Jul 1, 2022Goldman Sachs
Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18
Target:$18.00
+63.0%from $11.04
May 27, 2022Stifel Nicolaus
Stifel Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $13
Target:$13.00
+87.3%from $6.94
Apr 7, 2022Robert W. Baird
Iovance Biotherapeutics (IOVA) Stock: Why The Price Increased Today
Target:$34.00
+86.5%from $18.23
Apr 5, 2022Robert W. Baird
Iovance Biotherapeutics price target raised to $34 from $30
Target:$30.00
+81.2%from $16.56
Jan 28, 2022Stifel Nicolaus
Iovanace Biotherapeutics (IOVA) Stock: $25 Price Target From Stifel
Target:$25.00
+66.2%from $15.04
Jan 5, 2022Wells Fargo
Iovance Biotherapeutics price target lowered to $25 from $35 at Wells Fargo
Target:$25.00
+48.6%from $16.82
May 19, 2021Barclays
Iovance Biotherapeutics price target lowered to $40 from $60 at Barclays
Target:$40.00
+144.9%from $16.33

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance